EXCLUSIVE: Under FDA Lens, Mylan On Makeover Drive At Agila
This article was originally published in PharmAsia News
Executive Summary
The U.S. drug regulator served inspectional observations to Mylan’s Agila site in India as recently as February. In an exclusive discussion with PharmAsia News, the generic giant explained it continues to be confident about its capabilities in India and is bringing appropriate changes to establish a world-class injectables network.